PAVmed enters ATM sales agreement to sell up to $9.4M common stock

PAVmed Inc.

Agreement with A.G.P./Alliance Global Partners allows at-the-market sales of common stock up to $9,400,000.
Commission of 3.0% on gross sales; legal fee reimbursements up to $65,000 at execution, $7,500 quarterly, $12,500 per refresh.
Proceeds to be used for working capital and general corporate purposes.
Offering under existing shelf registration (File No. 333-283994) effective April 15, 2025; prospectus supplement filed Sept 9, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.